| Outcome and Timing | SOEa and Effect Estimate (95% CI) |
|---|---|
| Composite ischemic endpoints, in-hospital to 1 year | SOE = High (1 RCT, 2 observational studies; 106,749 patients) All studies showed statistically significant lowering of composite events in DAPT arm, ranging from RR 0.69 to OR 0.80; favors DAPT |
| Stroke, in-hospital to 1 year | SOE = Insufficient (1 RCT, 3 observational studies; 116,136 patients) Insufficient evidence due to inconsistency and imprecision: 3 out of 4 studies showed no statistically significant difference in stroke rates |
| Nonfatal MI, in-hospital to 1 year | SOE = High (1 RCT, 2 observational studies; 106,749 patients) All studies showed fewer recurrent MIs in DAPT group (2.3% to 5.8%) vs. aspirin alone (3.0% to 8.5%); favors DAPT |
| All-cause mortality, in-hospital to 1 year | SOE = Moderate (1 RCT, 4 observational studies; 117,467 patients) All studies showed fewer deaths in DAPT group, ranging from OR/RR 0.66 to OR/RR 0.93; favors DAPT |
| Major bleeding, in-hospital to 9 months | SOE = Low (1 RCT, 1 observational study; 105,607 patients) 2 studies showed a reduction in major bleeding in DAPT group (1 statistically significant [16% vs. 21%]; 1 not statistically significant); favors DAPT |
CI = confidence interval; DAPT = dual antiplatelet therapy; MI = myocardial infarction; OR = odds ratio; RCT = randomized controlled trial; RR = relative risk; SOE = strength of evidence
All SOE ratings of “Insufficient” (no evidence is available or available evidence is imprecise or too inconsistent to reach a conclusion) are shaded.
From: Executive Summary
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.